Problem

Andromeda Surgical targets a cognitive and access bottleneck in surgery: conventional surgical robots primarily improve physical manipulation, while difficult procedures still depend heavily on a surgeon’s orientation, judgment, and experience. Its initial use case is Holmium Laser Enucleation of the Prostate, or HoLEP, for benign prostatic hyperplasia. HoLEP can treat more than half a million U.S. patients annually, but its steep learning curve limits the number of urologists who can perform it. Surgeons may struggle to understand exactly where they are and what they are seeing during the procedure, creating mistakes and delays.

The economic pain is limited specialist capacity, inconsistent outcomes, and the cost of avoidable operating-room time. Andromeda’s thesis is that making surgery cognitively easier can improve outcomes, reduce costs, and let surgeons perform more procedures per day. HoLEP is the company’s killer use case because it is clinically established and algorithmically manageable, yet difficult enough to require substantial training.

Product / Service

Andromeda is developing a software-first surgical robotics platform that acts as an AI-guided assistant rather than simply a mechanically precise robot. Its spatial-navigation system is designed to function like GPS for human anatomy, giving surgeons real-time guidance through a procedure via an iPad interface. The company’s longer-term goal is surgeon-in-the-loop autonomy, in which proprietary models help execute increasingly sophisticated surgical tasks while the clinician remains involved.

The platform is designed to work with existing surgical tools and an open robotic architecture, using relatively light hardware and putting most of the value in software. Andromeda says its system can continuously improve through software updates and data from surgical cases, avoiding the need to replace the robot for every capability upgrade. The intended benefit is a shorter learning curve, greater procedural consistency, and broader access to expert-level surgical performance.

Market

Andromeda competes in AI-assisted surgical robotics, initially within endourology and natural-orifice procedures rather than the multi-port laparoscopic market served by most established surgical robots. The clearest broader incumbent is Intuitive Surgical’s da Vinci platform. In the initial BPH use case, the company also competes indirectly with conventional HoLEP and robotic simple prostatectomy, including da Vinci-based approaches; the public materials do not identify a direct robotic HoLEP competitor.

The company appears to be at the clinical-to-early-commercialization stage rather than operating as an established commercial product business. Founded in 2023 and accepted into Y Combinator’s Summer 2023 batch, it performed the world’s first robotic-assisted HoLEP procedure in Chile in December 2024, launched the ASTRA clinical study, reported 15 procedures in Chile and New Zealand by March 2025, and announced partnerships with Richard Wolf and Quanta System. Its LinkedIn page later reported a Health Canada medical-device licence, New Zealand clearance, and planned Canadian hospital cases, although the official website still carries a disclaimer saying the product is not commercially available and lacks regulatory approval. The company therefore has meaningful clinical and partnership traction, but its commercial revenue and final regulatory status remain unclear from the public record.